<DOC>
	<DOCNO>NCT02449564</DOCNO>
	<brief_summary>This study single-arm , phase II study sirolimus patient PIK3CA mutation PIK3CA amplication Refractory solid tumor . sirolimus 1mg administer orally qd daily . To investigate efficacy sirolimus patient PIK3CA mutation PIK3CA amplication Refractory solid tumor .</brief_summary>
	<brief_title>The Pilot Study Evaluate Safety Efficacy Sirolimus Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Provision fully inform consent prior study specific procedure . 2 . Patients must ≥20 year age . 3 . PIK3CA amplification and/or PIK3CA mutation Refractory Solid Tumors . 4 . ECOG performance status 02 . 5 . Have measurable evaluate disease base RECIST1.1 . determine investigator . 6 . Adequate Organ Function Laboratory Values Absolute neutrophil count ≥ 1.5 x 109/L , Hemoglobin ≥ 9g/dL , Platelets ≥ 100 x 109/L bilirubin ≤ 1.5 x upper limit normal AST/ALT ≤ 2.5 x upper limit normal ( 5.0 X upper limit normal , subject liver metastasis ) creatinine ≤1.5 x UNL 7 . Patients childbearing potential use adequate contraceptive measure ( two form highly reliable method ) breast feed must negative pregnancy test prior start dose . 8 . Adequate heart function . 1 . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease ≤5 year . 2 . Has know active central nervous system ( CNS ) metastases . 3 . Has active infection require systemic therapy . 4 . Pregnancy breast feed 5 . Patients cardiac problem .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>